Aquestive Therapeutics, Inc. (AQST)

Over the past six months, Aquestive Therapeutics' stock price has experienced notable fluctuations. In early January 2026, the stock declined significantly after the FDA identified deficiencies in the NDA for Anaphylm. On February 2, 2026, the stock surged despite receiving a Complete Response Letter from the FDA for Anaphylm, due to the market's perception that the FDA's requested additional information was less burdensome than anticipated. Aquestive plans to resubmit the Anaphylm application as early as Q3 2026. Investor alerts were issued by law firms in January 2026, investigating claims on behalf of Aquestive Therapeutics investors. The stock's 52-week range has been between $2.12 and $7.55.

No explicit information regarding demand seasonality for Aquestive Therapeutics, Inc.'s products and services was found in the provided search results.

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing differentiated products for unmet medical needs, particularly in CNS diseases and severe allergic reactions. The company utilizes its PharmFilm® technology for drug delivery. Aquestive's commercial product portfolio includes Libervant®, Suboxone, Sympazan, Emylif, KYNMOBI, and Azstarys. The company's pipeline includes Anaphylm™, AQST-108, AQST-305 and Adrenaverse™.

Aquestive Therapeutics is headquartered in Warren, New Jersey, and operates in the United States and internationally. The majority of its revenue is generated from the United States. The company also has four commercialized products marketed by its licensees globally, for which Aquestive is the exclusive manufacturer.

Aquestive Therapeutics has a consensus "Buy" rating from analysts, with an average rating score of 3.00. The company's stock has outperformed both the US Pharmaceuticals industry and the broader US Market over the past year. While the FDA's Complete Response Letter for Anaphylm initially caused a stock drop, the subsequent surge in stock price suggests that the market perceived the issues as manageable. Investor alerts from law firms in January 2026 indicate some scrutiny regarding the company's disclosures or stock performance during that period.

Aquestive Therapeutics, Inc. has 245 institutional owners and shareholders holding a total of 70,867,095 shares. Major institutional owners include Bratton Capital Management, L.P., BlackRock, Inc., RTW Investments, LP, Vanguard Group Inc., Perceptive Advisors Llc, EcoR1 Capital, LLC, Samsara BioCapital, LLC and Geode Capital Management, Llc. Individual retail investors hold the majority of the company's shares. Key individual insiders who own company stock include Daniel Barber, Cassie Jung, Peter E Boyd, and Carl N Kraus.